ホーム>>Signaling Pathways>> Immunology/Inflammation>> NOD-like Receptor (NLR)>>NOD-IN-1

NOD-IN-1

カタログ番号GC31657

NOD-IN-1 は、ヌクレオチド結合オリゴマー化ドメイン (NOD) 様受容体である NOD1 および NOD2 の強力な混合阻害剤であり、IC50 はそれぞれ 5.74 μM および 6.45 μM です。

Products are for research use only. Not for human use. We do not sell to patients.

NOD-IN-1 化学構造

Cas No.: 132819-92-2

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$102.00
在庫あり
1mg
$72.00
在庫あり
5mg
$135.00
在庫あり
10mg
$209.00
在庫あり
50mg
$702.00
在庫あり
100mg
$990.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.

NOD-IN-1 (compound 4) is potent mixed inhibitor of NOD1 and NOD2, displaying a balanced inhibitory activity on both targets in the low micromolar range. NOD-IN-1 (IC50 (NOD1)=5.74 μM; IC50 (NOD2)=6.45 μM) is identified as the best of the series, possessing NOD1- and NOD2-inhibitory activities in the lower micromolar range. These results show that NOD-IN-1 is 7-fold less potent than Noditinib-1 in terms of NOD1 inhibition and completely devoid of selective activity for NOD1 or NOD2 as opposed to Noditinib-1. NOD-IN-1 exhibits balanced dual activities of less than 10 μM on the two targets[1].

[1]. Kecek Plesec K, et al. Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2. Bioorg Med Chem. 2016 Nov 1;24(21):5221-5234.

レビュー

Review for NOD-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NOD-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.